Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the worlds largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

Our mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine. We relentlessly innovate to ensure our products and services support the evolving needs of precision medicine research. Our interdisciplinary team of data scientists, machine learning engineers, pathologists and biologists provide expert input and oversight into all our products and services.

Key leadership includes Viktor Matyas (Co-Founder & CEO), Maximilian Alber (Co-Founder & CTO), and other executives with strong expertise in AI, pathology, and biomedical research.

Aignostics started in 2018 within the walls of Charité Berlin and the Berlin Institute of Health, based on years of research. The company now has over 120 employees with a strong STEM background, including MDs and PhDs, across offices in Berlin and New York. They are ISO 13485 and 27001 certified and operate a GCP-ready clinical trial platform.

They offer precision medicine products such as Foundation Models for pathology and the Atlas H&E-TME tumor microenvironment profiling application. Their services include target and biomarker discovery, translational research, and digital diagnostics to accelerate drug development and clinical applications.